FDA approves Curasite™ Hydrogel Wound Care Product by JLM based Izun Pharmaceuticals

The FDA has approved the Izun Pharmaceuticals’ 510(k) application for Curasite™ Wound Care Hydrogel. Curasite™ is a proprietary topical combination of three botanical extracts: Centella asiatica, Echinacea purpurea and Sambucus nigra in a hydrogel base.

The prescription indications approved for use include the treatment of:

  • Diabetic foot ulcers
  • Leg ulcers, including venous stasis ulcers, arterial ulcers and ulcers of mixed etiology
  • Full and partial thickness pressure ulcers
  • 1st and 2nd degree partial thickness burns

The approved over-the-counter indications for use are:

  • Minor abrasions
  • Minor lacerations
  • Minor cuts
  • Minor scalds and burns

Izun Pharmaceuticals is based in Jerusalem.

For more information, see:

http://izunpharma.com/izun-pharmaceuticals-announces-approval-curasite-hydrogel-wound-care-product-fda/

Show Buttons
Share On Facebook
Share On Twitter
Share On Google Plus
Share On Linkedin
Hide Buttons